ObsEva Ending Nolasiban IVF Program As Phase 3 Study Fails
By Colin Kellaher
ObsEva SA (OBSV) on Thursday said a phase 3 study of nolasiban
missed its primary endpoint, and the biopharmaceutical company said
it would end its in-vitro fertilization program for the drug.
ObsEva said its European confirmatory study of nolasiban in
women undergoing embryo transfer following in-vitro fertilization
didn't meet the primary endpoint of an increase in ongoing
pregnancy rate at 10 weeks.
"We are extremely disappointed with these unexpected results,"
the Geneva-based company said, adding that it would explore
potential repositioning of the product candidate.
ObsEva licensed nolasiban, an oral oxytocin receptor antagonist,
from Merck KGaA (MRK.XE) and retains worldwide, exclusive
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
November 07, 2019 06:53 ET (11:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.